MedWatch

Analyst: Undramatic Lundbeck report shows fine growth for key products

Despite a slight disappointment on the top line in the third quarter of the year, a senior analyst at Sydbank thinks good key product growth more than compensates.

Photo: Jens Dresling

Lundbeck's third quarterly report of the year is largely as expected and relatively undramatic, assesses Senior Analyst at Sydbank, who nonetheless highlights the fact that sales growth of key products has accelerated in the period.

Lundbeck also maintains its financial guidance for the full year with expected operating profits of DKK 2-2.3bn (USD 311.1-404.5m), which also includes restructuring costs in the range of 100-200m (USD 15.6-31.1m) pertaining to the shutdown of the company's Indian operations and adjustments in the US-based business.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs